BMRA — BIOMERICA INC
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 73290 ·
Last close
$1.24
Market Cap
$5.68M
52W High
$2.94
52W Low
$1.01
ADV30
11,400
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Aug 2026 | 1,265,000 | 103,000 | -1,227,000 | -1,232,000 | 8,071,000 | 2,733,000 | 4,423,000 |
| May 2026 | 875,000 | -71,000 | -1,533,000 | -1,145,000 | 6,759,000 | 1,308,000 | 4,129,000 |
| Feb 2026 | 987,000 | -44,000 | -1,298,000 | -1,312,000 | 4,878,000 | 1,336,000 | 1,561,000 |
| Nov 2025 | 1,210,000 | 51,000 | -1,373,000 | -1,320,000 | 6,034,000 | 2,543,000 | 1,599,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,421,000
Investing CF
$-5,000
Financing CF
$2,334,000
CapEx
$-4,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.37
As of
2026-10-17
Balance + Analyst (yfinance extras)
Retained Earnings
$-56,943,000
Inventory
$1,707,000
Receivables
$785,000
ST Investments
—
EBIT TTM
$-5,322,000
Pretax Income TTM
$-3,753,000
Interest Exp TTM
$6,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,453,000
EBITDA
$-5,243,000
Free Cash Flow
$-2,297,000
Enterprise Value
$9,679,315
Total Cash
$1,308,000
Total Debt
$2,383,000
Shares Out
4,598,968
Trailing EPS
$-1.30
Book Value
$0.82
ROE
-112.1%
ROA
-52.3%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| May 2026 | 4,453,000 | -5,320,000 | -3,775,000 | 6,759,000 | 4,129,000 | 2,630,000 | -3,421,000 |
| May 2025 | 5,311,000 | -5,137,000 | -4,973,000 | 5,945,000 | 1,840,000 | 4,105,000 | -3,842,000 |
| May 2024 | 5,415,000 | -6,367,000 | -5,978,000 | 9,254,000 | 2,663,000 | 6,591,000 | -5,361,000 |
| May 2023 | 5,339,000 | -7,223,000 | -7,140,000 | 14,454,000 | 2,730,000 | 11,724,000 | -5,474,000 |
TTM Snapshot
Revenues TTM
$4,453,000
NetIncome TTM
$-3,775,000
OpCashFlow TTM
—
Assets (Latest)
$4,878,000
Forward EPS
$0.39
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CDIO | Cardio Diagnostics Holdings, Inc. | $5.06M | $1.71 | — |
| TRIB | TRINITY BIOTECH PLC | $4.89M | $6.01 | — |
| VNRX | VOLITIONRX LTD | $6.81M | $0.19 | — |
| AWHL | Aspira Women's Health Inc. | $7.00M | $0.15 | — |
| VSBC | VITASPRING BIOMEDICAL CO. LTD. | $3.21M | $0.02 | — |
News headlines (Yahoo Finance, 1h cache)
Biomerica Reports First Quarter Fiscal 2027 Financial Results
2026-10-16 12:19 · Yahoo
Biomerica Reports Fiscal 2026 Year-End Financial Results
2026-09-01 12:19 · Yahoo
Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs
2026-04-14 12:19 · Yahoo
Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
2026-04-16 12:19 · Yahoo
Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
2026-05-28 12:19 · Yahoo
Biomerica Reports Third Quarter Fiscal 2026 Financial Results
2026-04-13 22:57 · Yahoo
Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
2026-04-29 12:19 · Yahoo
Biomerica Announces $2.23 Million Financing
2026-08-27 12:19 · Yahoo
Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain
2026-03-05 13:19 · Yahoo
Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy
2026-02-26 13:19 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.